Skip to search formSkip to main contentSkip to account menu

XL019

Known as: JAK2 Inhibitor XL019 
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 2059: Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition
1 Co-treatment of XL019, a selective Jak2 inhibitor, highly sensitizes drug-resistant cancer cells by increasing P-gp inhibition… 
2014
2014
Balancing efficacy and safety of JAK inhibitors in myelofibrosis.
2012
2012
SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
2008
2008
EXEL-8232, a Small Molecule JAK2 Inhibitor, Effectively Treats Thrombocytosis and Extramedullary Hematopoiesis in a Murine Model of Myeloproliferative Disease Induced by MPLW515L
Approximately 50% of patients with essential thrombocythemia (ET) or myelofibrosis (MF) lack activating mutations in JAK2. Among… 
Highly Cited
2007
Highly Cited
2007
A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.
Since the identification of the JAK family of intracellular tyrosine kinases and their downstream signaling partners, the STATs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)